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Introduction: Clinical, biodiversity, and environmental biobanks share many data standards, but there is a lack
of harmonization on how data are defined and used among biobank fields. This article reports the outcome of an
interactive, multidisciplinary session at a meeting of the European, Middle Eastern, and African Society for
Biopreservation and Biobanking (ESBB) designed to encourage a ‘learning-from-each-other’ approach to
achieve consensus on data needs and data management across biobank communities.
Materials, Methods, and Results: The Enviro-Bio and ESBBperantoWorking Groups of the ESBB co-organized
an interactive session at the 2013 conference (Verona, Italy), presenting data associated with biobanking pro-
cesses, using examples from across different fields. One-hundred-sixty (160) diverse biobank participants were
provided electronic voting devices with real-time screen display of responses to questions posed during the
session. The importance of data standards and robust data management was recognized across the conference
cohort, along with the need to raise awareness about these issues within and across different biobank sectors.
Discussion and Conclusion: While interactive sessions require a commitment of time and resources, and must
be carefully coordinated for consistency and continuity, they stimulate the audience to be pro-active and direct
the course of the session. This effective method was used to gauge opinions about significant topics across
different biobanking communities. The votes revealed the need to: (a) educate biobanks in the use of data
management tools and standards, and (b) encourage a more cohesive approach for how data and samples are
tracked, exchanged, and standardized across biobanking communities. Recommendations for future interactive
sessions are presented based on lessons learned.
Introduction
The biobanking landscape comprises a diverse andexpanding collection of institutions, researchers, and
practitioners who, regardless of their different functions,
share a common need for best practices to implement data
standards, ethical regulations, and risk management.1,2
These regulatory, ethical, and operational standards must
continually evolve to keep biobanks in step with technical
and scientific advancements, and the present and future de-
mands of their stakeholders and clients. However, proce-
dures, policies, and standards are designed with limited
consideration given to the potential advantage of adapting
those created by other thematic biobanks. Encouraging and
sustaining cooperation and knowledge-sharing across
globally dispersed and diverse biobanks is challenging, and
scaling-up interactions is a limiting factor in terms of re-
sources, costs, and coordination.
Data constitute a ‘universal language’ across biobank dis-
ciplines as they are the result of sample collection, manage-
ment, and use. Additionally, genomics research technologies
that apply increasingly sensitive biomolecular analyses are
rapidly evolving, increasing the intrinsic value of all associated
data. In any biobank the value and utility of a biospecimen or
biological resource is determined by a) its fitness-for-purpose
(assurance that the quality of the biospecimen meets the
standard(s) of its end use; and b) the quality of the associated
and attributed information (information used to describe, an-
notate, and authenticate the biospecimen as well as the data
that provide a record of the processing and pre-analytical
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variables to which it has been exposed3). The greater the
quality of data linked to a biospecimen, the better a samplewill
be characterized and qualified for future use. A high-quality
sample isworthless if it has not been appropriately annotated or
is improperly supported by information that assures its identity
and quality, and describes its collection and use.10–16
In addition to preserving biospecimens as physical enti-
ties, biobanks need robust formats and standards to store
information about their processing such as a) permissions
including the ethical and regulatory documentation needed
to acquire, transfer, or collect biospecimens; b) data that
annotate collection, processing, and pre-analytical variables;
c) associated data related to environmental or clinical in-
formation which characterize a specimen and validate its
use; and d) data that enable standardized access and ex-
change of information (e.g., genomic sequencing data).
This article reports the outcome of a multidisciplinary,
interactive session at the 2013 ESBB meeting in Verona, Italy
entitled ‘‘The Life in Data,’’ designed by the Society’s
ESBBperanto and Enviro-Bio Working Groups. Individuals
from across the globe, representing diverse types of bio-
repositories and thematic disciplines, who would otherwise
have only limited opportunity to interact, were brought to-
gether to gauge their level of knowledge and opinions re-
garding existing data standards, and to provide a forum for
knowledge-sharing, debate, and consensus. Using a series of
biobank-related questions on specific topics, the interactive
session captured a ‘snapshot’ of informed opinion through a
real-time survey. Guidelines and a ‘tool’ for planning, de-
veloping, and delivering an interactive conference session are
presented as outputs of the experiences of the session plan-
ners, presenters, and participants. The value of incorporating
similar interactive sessions at future conferences is discussed.
Materials, Methods, and Results
The interactive session, which started with a poll of the
audience for demographic information, was designed to follow
the lifecycle of a biobank sample through the stages of per-
missions and consent, sample collection, sample classification,
research and data standardization. Each of these four stages
was illustrated by examples from the environmental, biodi-
versity, and clinical sectors. Each stage was comprised of three
parts—a scene-setting presentation, multiple-choice questions
to solicit audience opinions, and projection of results in real-
time with open discussion to provide continual interaction of
participants. The poll was conducted using TelevoterTM tech-
nology (Logos AV.COM., s.r.l.) with ShowvoteTM 2000
software collating and displaying the votes.
Audience demographics
Audience demographics were obtained at the start of the
session that involved 160 participants (Fig. 1). The partici-
pants represented primarily clinical medicine (55%), epide-
miology (10%), and translational research (17%). Participants
were funded primarily by public sources (65%) and industry
(10%). The amount of time participants had been working in
the biobanking field was 0–2 years (18%), 2–5 years (33%),
5–10 years (23%), and >10 years (20%); 5% were not in-
volved in biobanking. The majority (97%) agreed that sample
data quality management significantly impacts research
quality and reliability.
Permissions and consent
The first stage was focused on issues related to permissions
and consent, a crucial first step in biobanking. The Schistoso-
miasis Collection at the National History Museum (SCAN)4
was chosen as a case study to focus discussion. Schistosomiasis
is a parasitic, neglected tropical disease (NTD) infecting ap-
proximately 200 million people globally. Schistosomiasis is
caused by blood flukes (trematodes) with a life cycle that in-
cludes a snail intermediate host as well as the human or vet-
erinary definitive host. While no human samples are stored at
the SCAN repository, samples of parasite larval stages are
collected from donors along with associated, relevant demo-
graphic data.
FIG. 1. Audience demographics.
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The SCAN repository includes both the medical and en-
vironmental/biodiversity sectors. SCAN collaborates directly
with fieldwork-based projects such as the Schistosomiasis
Consortium of Operational Research and Evaluation, which
follows the International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals
for Human Use Good Clinical Practice (ICHGCP) guidelines
and complies with the World Medical Association’s De-
claration of Helsinki, 1964, amendment 2008.5
The related project, Zanzibar Elimination of Schistoso-
miasis Transmission,6 was used to describe the permission
and consent process. Key issues discussed in this session
included consent, open access to data, data protection, har-
monization, and benefit sharing.
International legal frameworks for biodiversity biobanks
were discussed using the example of the 1993 Convention
on Biological Diversity (CBD), which states that biodiver-
sity belongs to its country of origin. The CBD’s Nagoya
Protocol, which was ratified in 66 states (including the EU)
on October 12, 2014,7 addresses access and benefit sharing
agreement (ABS) permissions for the utilization of ge-
netic resources. Essential elements of the Nagoya Protocol
are prior informed consent, which must be obtained before
sample collection, and mutually agreed terms for how
benefits are shared. Material Transfer Agreements (MTA)
lay out terms of ownership crucial to the consent process,
for example, the Global Genome Biodiversity Network
(GGBN) agreed to a harmonized set of generic MTAs and
Code of Conduct for members.8
The first poll question asked was ‘‘What consent can re-
spect the patient/donor/provider without slowing research?’’
As shown in Figure 2a, 99% of the audience responded, 67%
selecting ‘‘Broad informed consent (open ended) with a right
to withdraw, provided there are appropriate measures to
safeguard sensitive data,’’ and 19% selecting ‘‘Specific in-
formed consent with a right to withdraw—new consents for
future work will be obtained where necessary.’’ One percent
of respondents were assigned to faulty electronics or ab-
stained from voting (equivalent to a 1% total error). A ma-
jority of 63% agreed on the need for more direction in the
form of an ESBB working group (Fig. 2b).
Sample collection
The utility of the Sample PREanalytical Code (SPREC, a
code for the ‘‘management and traceability of biospecimen
preanalytical variations’’) as a data quality management and
standardization tool was considered for clinical, environ-
mental, and biodiversity biobanks.9–12 The point of collection
was defined by subject and collector (field personnel, biobank
staff, and healthcare professionals). Standard Operating
Procedures (SOPs) and well-documented Work Instructions
(WIs) were considered essential for sample data quality
management, from the point of acquisition, throughout the
chain of custody and processing.
As some elements are outside the control of the biobank and
cannot be incorporated into the SPREC, good communication
between biobank personnel and the collectors was considered
vital to assure accurate data collection. This is dependent on
well-informed, non-biobank personnel such as nurses, physi-
cians, technical staff, field workers, and expedition teams.
Special effort must be taken to include additional instructions
that alert collectors (particularly non-biobank staff) to critical
factors (e.g., timing, stabilization, temperature, container
type). Explaining the significance of SPREC to collectors and
biobank staff was considered critical and should involve
training in sample and data collection techniques.
In responses to the question ‘‘What data should be captured
at the point of collection?’’ 74% of the audience chose both
‘‘pre-analytical variable data and data intrinsic to the sample
such as SPREC and non-SPREC related information,’’ the
remainder of the audience chose only one of the two responses
(Fig. 3). Thus, themajority vote conveyed a general consensus
regarding the need to include both SPREC and associated
(non-SPREC) data from the point of collection.
The audience concurred that a clear understanding of the
different types of data associated with sample collection is
necessary to describe and report sample status. This includes
data about collection variables, as well as the associated
information that defines the sample; both are vital to sample
quality and increase the value of the research and other
outcomes that are generated using biobanked samples. For
the secondary question, ‘‘Who collects the data at the point
of sample collection?’’, 78% of the audience responded that
both biobank staff and importantly non-biobank personnel
need to be trained in collecting and recording critical sample
acquisition data.
Sample classification
The value of a sample increases with the amount of asso-
ciated data including site and collection information, infor-
mation about the sample (e.g., disease definitions), and
additional analyses or associated images. The value of a
sample as defined by its associated data is clearly distin-
guishable from the fitness-for-purpose of a sample (quality).
However, the associated data may also describe a sample’s
fitness-for-purpose. This session focused on associated data
FIG. 2. Responses to survey questions related to permissions and consent. ESBB, European, Middle Eastern, and African
Society for Biopreservation and Biobanking.
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and the standards available, and used Biospecimen Reporting
for Improved Study Quality (BRISQ)13 as an example. The
purpose of this standard is to better understand, interpret,
compare, and reproduce experimental results that involve
human biospecimens. The use of BRISQ to describe research
biospecimens in publications has been recommended by the
Journal of Pathology,14Histopathology,15Nature Publishing
Group,16 and Biopreservation and Biobanking.17
Responses to questions related to sample classification
and associated data are shown in Figure 4. Responses to the
question ‘‘What else do you want to know about a sample?’’
revealed that data about the origin of a sample was most
important for 25% of the audience; 23% wanted to know
more about the phenotype, 33% were interested in sample
consent status, and 17% were unsure.
In response to the question ‘‘Do you think BRISQ should
be widely adopted as a publication standard?’’ 61% voted
yes with adaptions, 13% indicated yes, 9% said no, and 17%
were unsure.
Responses to ‘‘What do you think is the greatest hurdle
for why common ‘vocabulary’ is not used by biobanks?’’
indicated a lack of awareness of existing vocabularies (44%)
and the problems caused by not using controlled vocabu-
laries (34%).
Responses to ‘‘What areas of associated data have most
need of standardization?’’ were almost equally distributed
between phenotype data (34%), biospecimen data (31%), and
analysis data (21%), whereas 13% indicated they were unsure.
Research and data standardization
The last stage focused on the use of the sample and data
standardization and results are shown in Figure 5. The
question, ‘‘Which of the existing genomic standards is best
known to you?’’ was posed as a bridge to the previous stage.
A majority (72%) of the audience responded ‘none,’ 13%
were aware of Minimum Information about a Genome Se-
quence (MIGS),18 9% knew of the Sequence Read Archive
(SRA),19 and 7% knew of Access to Biological Collections
Data DNA (ABCDDNA).20
Given the development of genomic technologies and the
lack of knowledge of related standards, the focus was on
existing standards for genomic data sharing. While still using
the initial SCAN case study, the focus was on GGBN as an
FIG. 4. Responses to survey questions related to sample classification. BRISQ, Bispecimen Repository for Improved
Study Quality.
FIG. 3. Responses to survey questions related to data needed at the point of sample collection. SPREC, Sample PRE-
analytical Code.
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example of a large-scale, international consortium that is
establishing standards for data-sharing and publishing related
to genomics data. Published sequence data mostly lack in-
formation on the underlying specimens (vouchers).21 Vou-
chers are biological specimens containing morphological
parameters to allow taxonomic verification. They should be
deposited in collections (e.g., herbaria or other natural history
collections). The GGBN was formed in 2011 with the prin-
cipal goal of bridging the gap by making high-quality, well-
documented vouchered collections that store DNA or tissue
samples of biodiversity collections as well as corresponding
vouchers across the Tree of Life, available for research
through a networked community of biodiversity repositories.
The GGBN Data Portal (http://data.ggbn.org) is based on
established systems: GBIF (Global Biodiversity Information
Facility),22 BioCASe (Biological Collection Access Ser-
vice),23 IPT (Integrated Publishing Toolkit),24 and INSDC
(International Nucleotide Sequence Data Base Collabora-
tion).25 Each GGBN partner is responsible for its data and
samples, and defines conditions for access; scientists can
order samples easily via the shared portal. In the case of
SCAN, GGBN has to reconcile different sample types and
their associations with each other: intermediate host (snail)
specimen, snail DNA, parasite specimen, parasite DNA, and
relevant sequence data of the various sample types. So far,
GGBN is the only platform worldwide to globally aggregate
such biodiversity biobank data.
MIGS(MinimumInformation about aGenomeSequence)18
is a vocabulary designed by the Genomic Standards Con-
sortium for sharingDNAorRNAsequence information,which
provides minimum information about underlying environmen-
tal data. Based on MIGS, Darwin Core,26 and ABCDDNA,
GGBN has developed the GGBN Data Standard (http://
terms.tdwg.org/wiki/GGBN_Data_Standard) to be used
with environmental and single-species samples, as well as
DNA/RNA and sequence information. Furthermore it can
handle SPREC (http://terms.tdwg.org/wiki/ggbn:preparation
Process). When asked ‘‘Whether standards like SPREC,
BRISQ or MIGS should be combined with ABCD or Darwin
Core,’’ 41%of the audience agreed, 10% chose ‘no’, and 49%
were unsure (Fig. 5).
GGBN also promotes publication of negative results (e.g.,
failed amplification or sequencing); the audience was polled
on this issue with the majority (61%) agreeing that negative
results should be published, 28% agreeing to partial publi-
cation, 10% voting ‘no’, and 7% indicating they were un-
sure. Finally, the audience was asked if an infrastructure like
GGBN could work for human or environmental biobanks:
50% agreed, 43% were unsure, and 7% disagreed (Fig. 5).
Development of the interactive session tool
To provide sufficient time for audience participation, the
interactive session was held over 2 hours; the format included
four inter-related stages, each organized around a ‘core’ theme
or ‘hot topic’; and each stage lasted approximately 10minutes.
At the start of the interactive session, the participants were
familiarized with the relevant technology, and the audience
demographicsweredetermined.Each stage concludedwithone
or twomultiple-choice questionswith clear and understandable
options for response in order to understand the baseline com-
prehension and opinions of the audience and stimulate dis-
cussion based on a review of the results.
Participant responses were captured and visualized in
real-time, providing data that could be used to stimulate
real-time debate. Outcomes were collated and disseminated
to the conference participants. All data was made available
for further statistical analysis and a more detailed, post-
session interpretation.
Post-conference survey
The ESBB’s post-conference, online survey carried out
after the 2013 conference provided delegate feedback.
FIG. 5. Responses to survey questions related to research and data standardization. ABCD, Access to
Biological Collection Data; GGBN, Global Genome Diversity Network; MIGS, Minimal Information about a
Genome Sequence.
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Twenty-three percent (117) of the total number of confer-
ence attendees completed the online survey; 107 answered
questions pertaining specifically to the Life in Data Inter-
active session. Of these, 77 had participated in the confer-
ence, representing 18% of the total number of delegates who
had actively participated in the session.
A majority (73%) of the respondents were positive about
the interactive session, with 25% reportedly very satisfied
and 48% satisfied. Twenty-five percent had not attended the
session and 2% indicated dissatisfaction. Participants con-
sidered the format of the session an excellent way to poll the
views of the audience. The recommendation was made that
this kind of session should be continued at the annual ESBB
meetings, with some refinement to sustain levels of inter-
action and provide more time for discussion. Furthermore, it
was suggested that careful attention be given to the design
of questions to ensure that the audience is not being led to a
desired response.
Discussion
Audience demographics
While it would have been interesting to know whether
abstention from voting was higher for certain questions,
these data were unfortunately not available.
Representation from biodiversity and environmental bio-
banks was low compared to human biobanks; while this is
typical for ESBB and ISBER meetings it will not be the case
for nonclinical conferences. The categorization of biobank
areas was made using the type of research primarily sup-
ported by the biobank, as described in Watson et al.27 The
finding that little is known about data standards is surprising
as 86% of the audience had been working in biobanking for
>2 years. This is an area of concern as it implies a lack of
knowledge about available data standards. Although external
biobank stakeholders28 can help ensure biobank sustainabil-
ity, only 10% of the biobanks represented had funding from
the industry sector.
The question on the impact of data quality on research
outcomes was designed to get an understanding of the per-
spective of the audience before the session. As 97% voted
that the quality of sample data and the quality of its man-
agement had a significant impact on the quality and reli-
ability of research outcomes, it is even more surprising that
there was so little awareness of data standards. This is
consistent with recent publications that show that research is
often not reproducible due to selected reporting.29 More
than one-third of irreproducibility in pre-clinical research
results is reportedly due to the biological reagents and ref-
erence materials used, and about 25% is due to data analysis
and reporting issues.30 It would have been valuable to have
asked a question on the state of informatics at the organi-
zations represented by the participants, as well as the current
method of documenting data (electronic vs. paper). These
data could have provided a baseline of understanding upon
which to base an education program and would have been
related to the outcome of the survey of the ISBER Infor-
matics WG.31
Permissions and consent
The responses to the first question revealed that the ma-
jority preferred broad informed consent, indicating concern
that a specific consent process would slow research. As bio-
banking is a partnership between donors and researchers,
there is a need to balance and account for the requirements of
both groups.32 Responses to the second question indicated
dissatisfaction with current regulations and guidelines; a
dedicated ESBB working group was suggested to provide
support and direction for issues related to permissions and
consent such as third party use of material, implications of
storing data/samples in public repositories, management and
definition of benefit sharing, and balancing obligations with
the ability to do research. The Nagoya Protocol will result in
additional regulatory burdens with equivalent issues applying
to clinical biobanks when balancing patient privacy and the
need for research. One concern is the potential for genetic
exceptionalism and the impact on data sharing.33,34
Sample collection
The majority of the audience was involved in clinical
biobanks where data collection must be integrated with the
care of hospital patients involving non-biobank personnel
including nurses, clinicians, surgeons, and pathologists. The
same is true for biodiversity and environmental sample data
collection in remote sites where the logistics of sample
movement are difficult and rely on non-biobank personnel.35
While SPREC offers considerable latitude for sample an-
notation throughout the collection process,10 it does not
capture all significant associated data, some of which are
available in BRISQ.13
The importance of training collection staff in SPREC
and BRISQ tools according to biobank best practices2 was
highlighted during the interactive audience debate. SPREC
demonstrates how data quality management can be harmo-
nized across the research and biobanking sectors (see Nuss-
beck et al., 201312), although a comprehensive assessment of
the scope and utility of SPREC in relation to other reporting
tools is recommended. This will facilitate data management
from the point of sample collection throughout the entire
biospecimen process andwill address data standardization, an
important requirement both across and between biobanking
communities.36
Sample classification
When polling the participants on the information they want
to know about a sample (Fig. 4), the relatively balanced dis-
tribution of responses indicated thatmanymay havewanted to
select more than one option. Consent status received the most
votes (35%) indicating the need for satisfactory permissions
not only for use in human biobanks (audience majority), but
also for enviro-biobanks with the Nagoya protocol.7,34,37
While a previous survey in 2012 from the ESBBperanto
Working Group demonstrated that there is almost no stan-
dardization for BRISQ data across tumor biobanks,38 results
from our interactive session highlighted a consensus that
controlled vocabulary and terminology should be adopted as a
standard, but with adaptions according to need (61%). This is,
perhaps, an indication of why introducing standards is diffi-
cult as many biobanks consider their data requirements to be
unique. The lack of awareness of existing standards (44%) and
the consequences of not using a common vocabulary (34%)
clearly highlight the need for data standardization and use of
clear definitions and terminology.36,39
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Research and data standardization
Audience responses indicated a knowledge gap regarding
genomic standards. Despite the fact that genomic sequencing
is at the forefront of clinical and environmental research, 72%
of the participants were unaware of the existence of any such
standards. In an effort to explain this surprising response, the
audience was asked to indicate its involvement in genomic
research. The small number of responders underlined a lack
of awareness of standards in developing technologies and the
difficulty staying abreast of standards emerging from dif-
ferent disciplines, despite their potential multidisciplinary
applicability. It would appear that training workshops for
data standards and the use of common vocabularies would be
useful for future ESBB conferences.9–11,35,39–44
Interactive sessions
Conferences provide timely opportunities for geographi-
cally dispersed and operationally diverse communities to
come together. Interactive sessions enhance communication
between groups that would not usually interact. Greater
delegate participation is encouraged through recurrent in-
teraction with session presenters, and as such, the partici-
pants have the potential to direct the course of the session.
Sessions that focus on biobanking topics of special interest
facilitate the sharing and dissemination of information across
traditional thematic boundaries, and opinion polls create
opportunities to test consensus or divergence about common
topics of relevance to biobank communities in real-time.
Delivering interactive sessions at conferences enables
delegates to benefit from the presence of stakeholders,
vendors, clients, and beneficiaries in attendance, and they
have the potential for participation across the wider bio-
banking community. The inclusion of participatory formats
is inexpensive, and a less time-consuming alternative com-
pared to other types of interactions. Importantly, voting
provides immediate results and increases the possibility for
follow-up questions that can achieve real-time group con-
sensus or stimulate progression that can ultimately influence
global biobanking policies.
Interestingly, 20% of delegates at the ESBB 2013 session
responded to the post-conference online survey. In com-
parison, 64% of the participants present responded to the
questions posed during the session. This highlights a sig-
nificant increase in response to the real-time surveys in
comparison to online surveys, and demonstrates the potential
of this mechanism to increase responses to biobanking sur-
veys and questionnaires. Significantly, they empower par-
ticipants to vote anonymously on important issues and
identify gaps that can help to direct the future course of
biobank practice.
Recommendations for interactive sessions
The lessons learned from the ESBB’s first interactive
session have generated the following recommendations. It is
expected that these will be refined by the experiences of
future interactive session design and delivery teams.
FIG. 6. A ‘‘tool’’ for designing
and delivering an interactive con-
ference session.
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1. Time and resources. The creation of an interactive session
requires commitment of time and resources that need to be
confirmed before including the session in a program.
2. Presenter coordination. Delivery requires a coordinated
and consistent approach by topic presenters. Presenters in
interactive sessions must coordinate content development
and delivery of their topics to ensure that the ‘storyboard’
of the session is upheld throughout. This is distinct from
traditional conference session formats, which comprise
presentations developed independently and grouped into
a single session.
3. Design and moderation. Careful attention must be paid to
the construction and moderation of questions and an-
swers to stimulate delegate participation. It is important
that these are designed to be truly representative of all
conference participants and are non-biased to avoid
leading the audience to particular results.
4. Technology. Technology selected for future interactive
sessions should be able to display conclusive summary
graphics including absolute numbers of all answers from
the session to provide a final correlation of responses
from participants. The technology used in the pilot ses-
sion was limited in this respect.
5. Improving participant interactions. Selected technology
should allow questions and answers to be proposed and
presented in real-time as part of follow-up to interactive
discussions. The ability for participants to interact lends
itself to the development of virtual sessions for partici-
pants unable to attend the session. Future developments
for interactive sessions should permit the session to be
completely interactive so that the results of each topic
drive the direction of the subsequent one.
Conclusions
This publication reports on a successful pilot for a new
interactive session format that captures data from the bio-
bank community in situ at conferences. Simple guidelines
are presented and an interactive session ‘Tool’ (Fig. 6) has
been developed to enable the design of future sessions.
Lessons learned from this first pilot have highlighted the
need to develop communications and information technol-
ogies to increase the value of the interactive session by
providing total summary graphics and permitting real-time
presentation of questions that evolve during the session.
This interactive session among biobank representatives
highlighted theneed for communication and integrationbetween
clinical and nonclinical sectors on data standards, terminology,
definitions, andvocabularies. The use of data standards is pivotal
and some level of harmonization between the standards of
clinical and biodiversity biobank data is required. The joint
initiative of GGBN and ESBB is a step in this direction.
The interactive session provided a community response
that highlighted the need for education to increase the value
of the data collected. The development of an associated
common, controlled vocabulary accommodating harmonized
or equivalent terms would help with data compatibility for
wider sample/data querying and exchange. Significant inter-
est was shown for sharing of clinical and nonclinical data-
bases to provide a broader context such as correlating
metadata from the human, animal, plant, parasite, pollutant,
and environmental sectors to identify patterns of complex
conditions. The integration of these biobank data could help
answer larger questions about global health for all living or-
ganisms.
This exercise also demonstrated a lack of inter-disciplinary
knowledge, which could be addressed through more inter-
active sessions and workshops on this topic, building on the
outcomes of this first interactive session.
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